Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations

BACKGROUND: Anaplastic lymphoma kinase-positive (ALK+) and ROS proto-oncogene 1 (ROS1)-positive (ROS1+) lung cancers have been reported to be associated with an elevated risk of thromboembolic events. This study aimed to assess the long-term risk of developing thromboembolism (TE) in ROS1+ lung canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, H.-Y., Wu, S.-G., Lin, Y.-T., Chen, C.-Y., Shih, J.-Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808475/
https://www.ncbi.nlm.nih.gov/pubmed/36493600
http://dx.doi.org/10.1016/j.esmoop.2022.100742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808475/
https://www.ncbi.nlm.nih.gov/pubmed/36493600
http://dx.doi.org/10.1016/j.esmoop.2022.100742

Ejemplares similares